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Background: This study delineated correlations between ferritin, inflammatory biomarkers, and mortality in a cohort of
100 cancer-free patients with peripheral arterial disease (PAD) participating in the Veterans Affairs (VA) Cooperative
Study #410, the Iron (Fe) and Atherosclerosis Study (FeAST). FeAST, a prospective, randomized, single-blind clinical
trial, tested the hypothesis that reduction of iron stores using phlebotomywould influence clinical outcomes in 1227 PAD
patients randomized to iron reduction or control groups. The effects of statin administration were also examined in the
Sierra Nevada Health Care (SNHC) cohort by measuring serum ferritin levels at entry and during the 6-year study
period. No difference was documented between treatment groups in all-cause mortality and secondary outcomes of death
plus nonfatal myocardial infarction and stroke. Iron reduction in the main study caused a significant age-related
improvement in cardiovascular disease outcomes, new cancer diagnoses, and cancer-specific death.
Methods: Tumor necrosis factor (TNF)-, TNF- receptors 1 and 2, interleukin (IL)-2, IL-6, IL-10, and high-sensitivity
C reactive protein (hs-CRP) were measured at entry and at 6-month intervals for 6 years. Average levels of ferritin and
lipids at entry and at the end of the study were compared. The clinical course and ferritin levels of 23 participants who died
during the study were reviewed.
Results: At entry, mean age of entry was 67  9 years for the SNHCS cohort, comparable to FeAST and clinical and
laboratory parameters were equivalent in substudy participants randomized to iron reduction (n  51) or control (n 
49). At baseline, 53 participants on statins had slightly lower mean entry-level ferritin values (114.06 ng/mL; 95%
confidence interval [CI] 93.43-134.69) vs the 47 off statins (127.62 ng/mL; 95% CI, 103.21-152.02). Longitudinal
analysis of follow-up data, after adjusting for the phlebotomy treatment effect, showed that statin use was associated with
significantly lower ferritin levels (29.78 ng/mL; Cohen effect size, 0.47 [tdf, 134  2.33, P  .02]). Mean follow-up
average ferritin levels were higher in 23 participants who died (132.5 ng/mL; 95% CI, 79.36-185.66) vs 77 survivors
(83.6 ng/mL; 95% CI, 70.34-96.90; Wilcoxon P  .05). Mean follow-up IL-6 levels were higher in dead participants
(21.68 ng/mL; 95% CI, 13.71-29.66) vs survivors (12.61 ng/mL; 95% CI, 10.72-14.50; Wilcoxon P  .018). Ferritin
levels correlated (Pearson) with average IL-6 levels (r 0.1845; P .002) and hsCRP levels (r .1175; P .04) during
the study.
Conclusion: These data demonstrate statistical correlations between levels of ferritin, inflammatory biomarkers, and
mortality in this subset of patients with PAD. (J Vasc Surg 2010;51:1498-503.)
Clinical Relevance: This research examined relationships between iron storage and inflammatory biomarkers in a cohort
of 100 cancer-free PAD patients with peripheral arterial disease from the Veterans Affairs (VA) Sierra Nevada Health
Care System (SNHCS) cohort participating in a prospective, randomized, single-blind, clinical trial to test the hypothesis
that iron in excess of physiologic requirements promotes atherosclerosis. Calibrated phlebotomy was used to reduce iron
storage in risk factor-matched participants. The main study, VA Cooperative Study (CSP) 410, demonstrated clinical
benefits in reduction of death from primary and secondary end points for participants aged between 43 and 61 years. This
SNHCS substudy demonstrated significant relationships between total body iron stores as determined by ferritin,
inflammatory cytokines, and high-sensitivity C-reactive protein (hsCRP). Ferritin levels positively correlated with
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Volume 51, Number 6 DePalma et al 1499interleukin-6 levels and hsCRP levels, whereas ferritin and interleukin-6 levels were significantly higher in participants
who died vs survivors. Statin administration reduced ferritin levels independently of phlebotomy, indicating an effect of
these agents on iron metabolism. Our findings support a biologic rationale for measurement of serial ferritin levels in
patients with atherosclerosis. Because iron-induced oxidative stress contributes to inflammatory responses, determination
of optimal ironmarker levels to bemaintained by calibrated phlebotomy is a clinically relevant concept for future outcome
studies.This report describes correlations between ferritin lev-
els, inflammatory biomarkers, and mortality at entry and at
6-month follow-up intervals during the 6-year study dura-
tion obtained from 100 consenting Sierra Nevada Health
Care (SHNC) participants in the Iron (Fe) and Atheroscle-
rosis Study Study (FeAST), Veterans Affairs (VA) Cooper-
ative Study (CSP) #410. The FeAST study tested the
concept that iron-induced oxidative stress might provide
inflammatory stimuli in atherosclerosis.1-11 Relationships
between iron status (ferritin levels) and inflammatorymark-
ers at entry before randomization and during follow-up
were explored in the SNHCS subset participants regardless
of randomization status.
The FeAST trial (1999 to 2005)12 used phlebotomy to
test the iron hypothesis. The trial randomized 1277 previ-
ously cancer-free participants with advanced but stable
peripheral arterial disease (PAD) from 24 VA Medical
Centers to graded reduction of iron stores by calibrated
phlebotomy vs a nonphlebotomy control group. Details of
study design and execution have been reported.12 Ran-
domization variables at entry included age, ferritin and
cholesterol levels, smoking status, and diabetes status. The
primary outcome was all-cause mortality and the secondary
outcome was death plus nonfatal myocardial infarction and
stroke. Data on cardiovascular disease (CVD) outcomes
and on the occurrence of new cancer diagnoses and cancer-
specific deaths were collected prospectively and analyzed on
intent-to-treat basis.
Overall, no significant differences between treatment
groups for primary or secondary end points were detected.
However, secondary analysis by randomization variables
showed that age interacted significantly with treatment.
The hazard ratios from the Cox proportional hazard regres-
sion model were used to compare primary and secondary
end points. Significant improvement with younger age at
entry was observed for the secondary end point (P  .004
for interaction). Significant improvement in primary (P 
.02) and secondary (P  .001) end points was observed in
the youngest age quartile participants (age 43 to 61) ran-
domized to iron reduction compared with control.12 Iron
reduction resulted in a 37% lower incidence of new cancer
diagnoses (P  .025), reduced risk of new cancer by
Kaplan-Meier (P  .04) and cumulative incidence analysis
(P .02), and reduced cancer-specificmortality (P .003)
and all-cause mortality in participants diagnosed with can-
cer (P .009).13 Risk reduction began6 months, corre-
lated with compliance, and occurred across the entire age
spectrum. Minimal cancer risk was observed, with mean
follow-up ferritin levels 57 ng/mL.13A prior SNHCS exploratory study demonstrated ele-
vated levels of inflammatory cytokines in PAD participants
compared with controls along with effects of phlebotomy
at 6months on ferritin levels and reduction of inflammatory
cytokines in the upper quartile of values.14 The present
substudy tracked relationships between average levels of
ferritin, cytokines, and high-sensitive C-reactive protein
(hsCRP), and statin use in the SNHCS cohort during the 6
years of the trial.
METHODS
All investigations in this study were performed accord-
ing to protocols approved by the VA SNHCS Research and
Development Committee and the University of Nevada
Biomedical Instructional Review Board, including retro-
spective use of serum samples after death.
From 1999 to 2005, the study monitored 100 partici-
pants from the VA SNHCS who were a mean age of 67
years (range, 45-82). Of these, 51 were randomized to
phlebotomy and 49 to a control group.Mortality outcomes
were recorded according to intent-to-treat, age at death,
and cause of death.
Calibrated phlebotomy was performed according to
the formula used in the FeAST overall study.12 (Ferritin
ng/mL 25)  10  mL blood to be removed. The
primary and secondary age-related end points for the
SNHCS cohort were calculated in a similar manner to that
used in the overall FeAST study using Kaplan-Meier com-
parisons. The Cox proportional hazard regression model
was used to compute hazard ratios (HR) and 95% confi-
dence intervals (CI), with adjustment to covariates for
analyses of primary and secondary outcomes. No significant
differences were detected in the SNHCS cohort.
The proportion of participants receiving statins was
tracked throughout the study. The effect of statins on
ferritin levels was assessed using a longitudinal multivariate
model SAS PROC MIXED15 for the SNHCS cohort and
for all the FeASTmain study participants. Themodel tested
the main effects using follow-up ferritin as the dependent
variable. Independent variables were phlebotomy (iron re-
duction vs control), statin use at each follow-up, and other
baseline covariates. Biomarkers measurements, including
ferritin, cytokines, and hsCRP, were analyzed by methods
previously described.14,16 Inflammatory cytokines tumor
necrosis factor (TNF), TNF-R1 and R2, interleukin
(IL)-6, and anti-inflammatory cytokines interleukin (IL)-2
and IL-10 were analyzed by enzyme-linked immunosor-
bent assay at baseline and every 6 months and correlated
with ferritin levels in all participants, as described in prior
reports.14,16 Because cytokine values are not normally dis-
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statistical analyses. Baseline average levels of ferritin, cho-
lesterol, low-density lipoprotein, high-density lipoprotein,
and triglycerides in control and intervention groups were
compared at entry and at 6-month intervals to the end of
the trial using the Wilcoxon rank-sum method. The entry
and final values were tabulated.
RESULTS
Twenty-three participants died during the study: 12
among the 51 assigned to the iron-reduction group and 11
among the 49 in the control group. The causes of death in
the iron-reduction group were cancer in 3, CVD in 6, and
other (eg, trauma) in 3; and in the control group were
cancer in 2, CVD in 5, and other causes in 4. The primary
and secondary end points were similar to those in the main
study using identical analyses. Three of the 51 participants
randomized to phlebotomy subsequently declined this in-
tervention, resulting in a 94% compliance rate.
The maximum ferritin reduction occurred between
baseline levels and the first 6-month follow-up value, after
which ferritin levels tended to plateau. By intent-to-treat
analysis, the time to death was 21 to 65 months in the 12
patients in the iron-reduction group and 5 to 49 months in
the control group. The Cox proportional hazards model
was used to analyze survival times. The HR were 1.005
(95% CI, 0.443-2.280; P  .9896) for deaths and 1.205
(95% CI, 0.598-2.425; P  .602) for secondary events in
the SNHS cohort. The difference between the control and
phlebotomy groups was not significant.
The association between death and elevated ferritin
levels and inflammatory cytokines was related to the aver-
age of values during the entire 6-year study. The time
between the last ferritin levels obtained in stable SNHS
patients, according to the FeAST protocol was an average
of 245 days (median, 124; range, 3-1583 days). An 81-
year-old patient, who was a noncompliant participant in the
intervention group, died after bronchoscopy 3 days after a
ferritin determination of 300 ng/mL. After review of all
entry and terminal ferritin levels among the 23 deaths, only
this single instance would represent an acute-phase reaction
involving an elevated ferritin level.
FeAST protocols required exclusion of participants
with a history of malignancy, disturbance in iron metabo-
lism, hepatic or renal abnormalities, recent infection, anti-
biotic administration, or bleeding event because such overt
conditions are capable of affecting ferritin levels. If ferritin
levels were elevated in a participant who had an infection or
inflammatory process, a ferritin level was repeated after the
infection or inflammatory process subsided and only then
was phlebotomy performed. Phlebotomy was withheld for
those who refused and for those in unstable conditions.
To examine the possibility that ferritin levels and bi-
omarkers were possibly related to underlying disease states,
Pearson correlation coefficients were used to examine rela-
tionships between serum measures and body mass index
(BMI), diabetes, and smoking. A direct relationship be-
tween ferritin and IL-6 levels was observed that was main-tained after correction for BMI, diabetes, and smoking
status in all participants and survivors. The observed rela-
tionship between ferritin and CRP levels was maintained
after corrections for BMI, diabetes, and smoking status
only in survivors.
Table I reports the relationship between the mean
ferritin level during the study period and mortality for each
intervention group and for patients combined; the data
were analyzed using the Wilcoxon test. The mean ferritin
levels during the entire follow-up period in the 23 nonsur-
viors was 132.5  116.8 ng/mL, which was significantly
higher than the level of 83.6  57.3 ng/mL in the survi-
vors (Wilcoxon, P  .05). Thus, the average ferritin level
appeared to be directly related both to mortality and levels
of inflammatory biomarkers.
An important confounder addressed in the current
substudy related to statin use, which was not a criterion for
randomization into FeAST. At baseline, 47 participants not
receiving statins exhibited a trend toward higher mean
ferritin levels of 127.6 ng/mL (95% CI, 103.21-152.02)
compared to 114.06 ng/mL (95% CI 93.42-134.69) in
the 53 who were receiving statins. This difference was not
statistically significant. During the study, however, 31more
participants began taking statins, and these agents were
discontinued in 18 participants at different times. Longitu-
dinal analysis (SAS PROCMIXED)15 of all follow-up data
showed, after adjusting for the phlebotomy treatment ef-
fect, that statin administration had a significant effect on
the reduction of ferritin levels (29.78 ng/mL) with a
Cohen effect size of 0.47 (tdf  134  2.33; P  .02).
Table II reports the Pearson correlation coefficients
between levels of ferritin, cytokines, and hsCRP in the
100 participants, including the 77 survivors and 23
nonsurvivors. Significant relationships were found be-
tween levels of ferritin and IL-6 (r  0.1845, P  .002)
and hsCRP (r 0.12, P .04). Ferritin levels correlated
with IL-6 levels in surviving participants (r  0.21, P 
.002), but IL-6 and ferritin were significantly higher in
Table I. Mean follow-up ferritin levels and intervention
during study period in survivors and nonsurvivors in the
Sierra Nevada Health Care cohort of the Veterans Affairs
Cooperative Study #410
Treatment group Participants Ferritin level Pa
No. Mean  SD, ng/mL
Control .60
Survivors 38 111.1  65
Nonsurvivors 11 159.5  158.3
Iron reduction .05
Survivors 39 56.2  29.9
Nonsurvivors 12 112.3  74.2
Total .05
Survivors 77 83.6  57.3
Nonsurvivors 23 132.5  116.8
SD, Standard deviation.
aAnalyzed by the Wilcoxon test.participants who died than in survivors. Mean follow-up
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the 23 participants who died compared with 12.61
ng/mL in the 77 survivors (95% CI 10.72-14.50; P 
.02). No correlations were found among ferritin levels,
TNF-, IL- 2, and IL-10.
Ferritin levels correlated (Pearson) with hsCRP levels
(r  0.12, P  .04) for all participants and for survivors
(r  0.16, P  .01). CRP is of interest because this is the
commonly accepted clinical biomarker for gauging an in-
flammatory response. Table III reports CRP level correla-
tions with TNF-R1 (r  0.17, P  .003) and R2 (r 
0.386, P  .0001) for all participants and for survivors for
R1 (r 0.20, P .002) and R2 (r 0.41, P .0001). No
correlation between CRP and ferritin levels was detected in
the 23 participants who died.
Table IV summarizes Wilcoxon rank-sum testing for
the average baseline ferritin levels before intervention,
which were comparable at 116  73.1 ng/mL in the
control group and 124  85 ng/mL in the iron-reduction
group (P  .99). Ferritin levels at the point of last follow-up
and lipid values are included to compare differences. At the
last follow-up, ferritin levels in controls averaged 120.5 
90.6 ng/mL and 69.9  50.3 ng/mL in the iron-reduction
group (P  .0003). No significant differences occurred
between entry values and last follow-up values for choles-
terol, high-density and low-density lipoprotein, and trig-
Table II. Pearson correlation coefficients (r) between ferr
in Veterans Affairs Sierra Nevada Health Care cohort of C
Group IL6 CRP T
All participants (N  100)
Ferritin
r 0.18 0.12 
P .002 .04
Survivors (n  77)
Ferritin
r 0.21 0.16 
P .002 .01
Nonsurvivors (n  23)
Ferritin
r 0.10 0.05 
P .47 .68
CRP, C-reactive protein; IL, interleukin; TNF-, tumor necrosis factor .
Table III. Correlations during the study period between
C-reactive protein and tumor necrosis factor- (TNF-)
receptors in Veterans Affairs Sierra Nevada Health Care
cohort of Cooperative Study #410
Group No.
TFN- R1 TNF- R2
r P r P
All participants 100 0.17 .003 0.38 .0001
Survivors 77 0.20 .003 0.41 .0001
Nonsurvivors 23 0.10 .45 0.19 .15lycerides.DISCUSSION
This study demonstrated an association between levels
of ferritin, inflammatory cytokines, and hsCRP in a subset
of 100 individuals with PAD during a clinical trial of iron
reduction. Overall age at entry andmortality in the SNHCS
cohort during the trial paralleled the overall results of the
main FeAST trial of 1277 participants.12 Levels varied
widely in both the iron-reduction and control groups; the
intervention group overall showed an average terminal
reduction of ferritin levels to about 70 mL. However,
statistical correlations between ferritin, inflammatory bi-
omarkers, and death occurred during the course of the trial
evels, cytokines, and biomarkers during the study period
rative Study #410
TNFa R1 TNFa R2 IL-2 IL-10
0.02 0.04 0.05 0.04
.76 .50 .46 .48
0.04 0.01 0.02 0.20
.54 .85 .16 .77
0.006 .24 0.07 0.09
.96 .05 .06 .48
Table IV. Initial average ferritin and lipid levels at
baseline and at last follow-up in the Veterans Affairs
Sierra Nevada Health Care cohort of Cooperative Study
#410
Variable Control Iron reduction Pa
Ferritin, ng/mL
Baseline 116.4  73.1 124.2  84.5
Follow-up 120.5  90.6 69.9  50.3
Difference 5.6  66.9 53.3  88.2 .0001
Cholesterol, mg/dL
Baseline 187.4  37.6 197.1  39.7
Follow-up 184.2  30.2 185.1  29.5
Difference 3.2  32.7 11.7  34.1 .63
HDL, mg/dL
Baseline 42.6  17.6 45.8  14.5
Follow-up 40.3  16.9 45.3  15.7
Difference 2.4  7.9 0.7  9.5 .54
LDL, mg/dL
Baseline 118.6  33.6 125  33.5
Follow-up 115.5  24.9 113.4  27.3
Difference 2.3  27 9.7  28.4 .46
Triglycerides, mg/dL
Baseline 175.7  134.5 171.6  86.2
Follow-up 175.3  94.7 165.1  105.8
Difference 2.5  92.5 7.8  81.6 .12
LDL, Low-density lipoprotein; HDL, high-density lipoprotein.
aAnalyzed by the Wilcoxon test.itin l
oope
NFa
0.04
.48
0.02
.78
0.15
.22irrespective of intervention assignments. These data derive
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phlebotomy intended to deliberately lower ferritin levels,
which as in the main trial, did not affect overall mortality.
However, the data in the present study highlight compli-
ance issues related to achieved ferritin levels, related inflam-
matory cytokine levels, and mortality that occurred regard-
less of allocation to phlebotomy or control groups.
These correlations appear to provide biologic support
to the previously reported secondary analyses of the main
FeAST trial during which secondary data analyses demon-
strated participants aged 43 to 61 years received major
benefits.12 The predictive value of IL-6 for death in the
present study was a notable finding. This inflammatory
cytokine appeared as a highly specific marker for death.
CRP alone did not predict death in the SNHCS cohort or
differentiate between participants who were or were not
receiving statins. In addition, hsCRP levels did not differ
between survivors and nonsurvivors, participants random-
ized to control or intervention groups, or between diabetic
and nondiabetic participants. These discordances may re-
late to the effect of small sample size, and further studies are
needed. Our prior report14 in 2003 demonstrated a strong
relationship between advanced PAD and elevated hsCRP
and inflammatory cytokine levels compared with healthy
controls studied at the beginning of the FeAST trial.
Relationships of statin administration to biomarkers at
the time of entrance into FeAST before randomization,
based on physician preference, were described in a prior
report.16 At that time, 53% of participants entering the
study were receiving statins. A significant proportion of
these were diabetic patients who also exhibited significantly
elevated IL-6 levels that were apparently not reduced by
statin use. With subsequent randomization, the direct rela-
tionship between ferritin and IL-6 levels was not affected by
diabetes or BMI in all participants or in survivors. Evolving
prescribing standards during the period of the trial (1999
to 2005) recommended statin use for all patients with
PAD. In accordance with practice recommendations for
PAD, statin use prescriptions commenced in 31 SNHCS
participants, and 18 participants discontinued statins for
unspecified reasons. After adjusting for phlebotomy effect,
statin use remained associated with significantly lower fer-
ritin levels.
Statin use was not taken into account during random-
ization for the CSP #410 FeAST trial, and the evolving
practice of prescribing statins for PAD during the study
interval was likely a confounding factor. The effect of statins
in association with reduced ferritin levels is a provocative
finding suggesting a possible mechanism of action of these
agents on iron metabolism. The mechanism of statin effect
on biomarkers and its pleiotropic anti-inflammatory actions
requires further study taking into account duration of
treatment, dosage, and type of agent.
During the study period, ferritin levels in the phlebot-
omy group fell from an average of 124.2 to 69.9 ng/mL,
measured at 6 months after the preceding phlebotomy.
Future trials might aim for sustained lower ferritin levels,
such as 25 to 40 ng/mL, throughout the study interval.Such levels might be obtained with ideal compliance with
phlebotomy. The present substudy, which showed un-
equivocally higher ferritin levels in participants who died
than in survivors, irrespective of assignment to control or
phlebotomy strategy, supports this view.
Interrelationships between iron storage, ferritin levels,
and biomarkers are multiple, complex, and interactive.
These require further delineation using prospective, ran-
domized studies sufficiently powered to demonstrate spe-
cific subgroup correlations, biomarker profiles, and out-
come effects. Selection of younger participants, along with
a more robust continuum of reduced ferritin levels into
prospective trials, appears desirable. The finding of statisti-
cally significant correlations between ferritin and high levels
of inflammatory cytokines IL6 and TNF- R1 and R2 sug-
gests biologic relationships between increased ferritin levels
and the inflammatory biomarker responses associated with
atherosclerosis and its complications. Ferritin in stable-state
patients is considered to be the preferred marker of clinical
outcomes that are presumably caused by iron-related
stress.17
Although causality cannot be inferred from the present
study on purely statistical grounds, a recent comprehensive
review18 suggests that poorly liganded iron species lead to
the catalytic production of highly damaging pro-oxidant
radicals. These are thought to be a major cause of chronic
inflammation contributing to vascular and other progres-
sive inflammatory diseases.
More prospective studies are required before iron-
reduction strategies for atherosclerosis can become
mainstream recommendations. However, the present ex-
ploratory study supports a rationale for serial measure-
ments of ferritin levels, not only for assessing the role of
iron storage in atherosclerosis but also as a means of
screening for iron storage diseases, for example hemo-
chromatosis.
Although the United Blood Service makes no claim for
the health benefits of blood donation by healthy individu-
als, a number of positive reports describe improved health
in regular blood donors,19 who may donate between four
to six times yearly with hematocrit in excess of 38%. Some
disagree with these observations.20 The benefits of iron
reduction by phlebotomy might prove most favorable for
women who do not menstruate and for younger men as
well as for other accepted indications to lower iron stores.19
Additional measures to reduce excess iron stores include
avoidance of iron-containing supplements and eating less
red meat. Iron supplementation of flour has now been
abandoned in Scandinavia.21 Chelators such as defera-
sirox22-23 and other agents are available to reduce iron
stores. Vascular specialists might consider measurement of
ferritin levels along with assessing levels of lipids and
hsCRP. Sequential measurements of IL-6, CRP, and addi-
tional inflammatory biomarkers may prove helpful for
prognosis and for analyzing biologic events and relating
these eventual outcomes.
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Positive statistical correlations between ferritin levels,
inflammatory cytokines, CRP, and mortality suggest that
iron-induced oxidative stress may relate to inflammatory
responses in PAD. The biomarker correlations described in
this study provide conceptual support for further trials that
investigate reduction of mortality using robust iron reduc-
tion strategies.
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